Redmile Group, LLC - 25 Aug 2025 Form 4 Insider Report for Shattuck Labs, Inc. (STTK)

Role
Director, 10%+ Owner
Signature
By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
Issuer symbol
STTK
Transactions as of
25 Aug 2025
Net transactions value
$0
Form type
4
Filing time
26 Aug 2025, 17:00:29 UTC
Previous filing
15 Aug 2025
Next filing
28 Oct 2025
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Redmile Group, LLC Director, 10%+ Owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC 26 Aug 2025 0001425738
Green Jeremy Director, 10%+ Owner C/O REDMILE GROUP, LLC (NY OFFICE), 45 W. 27TH STREET, FLOOR 11, NEW YORK /s/ Jeremy Green 26 Aug 2025 0001650527

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STTK Pre-Funded Warrants to Purchase Common Stock Award +4,097,730 +132% 7,198,553 25 Aug 2025 Common Stock 4,097,730 $0.000100 See Footnotes F1, F2, F3, F4
transaction STTK Common Warrants to Purchase Common Stock Award +4,097,730 4,097,730 25 Aug 2025 Common Stock 4,097,730 $1.08 See Footnotes F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Redmile Group, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On August 25, 2025 (the "Closing Date"), pursuant to the terms of that certain securities purchase agreement, dated as of August 4, 2025 (the "Purchase Agreement") and following the satisfaction of certain material conditions set forth therein, the Issuer issued and sold to certain institutional investors in a private placement, including certain private investment vehicles managed by Redmile Group, LLC (the "Redmile Clients"), pre-funded warrants (the "Pre-Funded Warrants") to purchase shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), accompanied by warrants (the "Common Warrants") to purchase an equal number of shares of Common Stock (or, in lieu thereof, Pre-Funded Warrants to purchase up to the same number of shares), at a combined purchase price for both securities of $0.8676.
F2 The Pre-Funded Warrants and Common Warrants are exercisable by the holder at any time on or after the Closing Date, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants do not have an expiration date. The Common Warrants will expire 30 days after a public announcement of the data from the Issuer's Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trial.
F3 The reported securities are directly owned by the Redmile Clients, and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as the investment manager of the Redmile Clients.
F4 The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks:

Mr. Michael Lee, a managing director of Redmile, resigned as a member of the board of directors of the Issuer effective as of the Closing Date.